This dual mechanism produces greater weight loss, and the addition of GIP signaling may have unique interactions with the metabolic state of ketosis that pure GLP-1 agonists do not
TRIUMPH-3, conducted in people with type 2 diabetes who have obesity or overweight, likewise met its endpoints, delivering significant improvements in both body weight and HbA1c
The average outcome is still medically significant and transformative for most people
Reduces Appetite: GLP-1 acts on the brain to decrease appetite and increase feelings of satiety, which can lead to weight loss
And sun protection becomes even more important, because with reduced subcutaneous fat, the skin is more vulnerable to UV-induced photoaging
Diabetes and Metabolism Reviews, 15(2), 120-132